🎙️Episode 7: EV-302 Trial on Enfortumab Vedotin + Pembrolizumab in Advanced Urothelial Carcinoma 🎙️ скачать в хорошем качестве

🎙️Episode 7: EV-302 Trial on Enfortumab Vedotin + Pembrolizumab in Advanced Urothelial Carcinoma 🎙️

In this episode, host Christina and Dr. Pidugu dive deep into the groundbreaking results from the EV-302 trial, a pivotal phase 3 study published in the New England Journal of Medicine. This trial evaluates the efficacy and safety of combining Enfortumab Vedotin (an antibody-drug conjugate) with Pembrolizumab (a PD-1 inhibitor) as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma. Key Highlights: • What is urothelial carcinoma and why current treatments fall short • Mechanism of action: Enfortumab Vedotin & Pembrolizumab • EV-302 trial design and key endpoints (OS, PFS, response rates) • Results: Doubling of overall survival and improved response rates • Safety profile and side effect comparison with chemotherapy • Limitations and future directions Why this matters? For years, platinum-based chemotherapy has been the standard first-line treatment for advanced urothelial carcinoma. The EV-302 trial may signal a paradigm shift—offering significantly better survival outcomes with a manageable safety profile. 🎧 Whether you're a clinician, researcher, or patient advocate, this episode provides an accessible breakdown of how clinical trials are reshaping oncology practice. 🔗 Resources Mentioned: N Engl J Med 2024;390:875-888 DOI: 10.1056/NEJMoa2312117 NEJM Article: “Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer” 👍 If you found this episode valuable: ✅ Like ✅ Subscribe ✅ Share with colleagues or anyone affected by bladder cancer 🧪 Stay tuned for future episodes covering cutting-edge trials in oncology. #BladderCancer #UrothelialCarcinoma #EV302 #EnfortumabVedotin #Pembrolizumab #Immunotherapy #CancerTrials #OncologyPodcast #ClinicalTrials #OncoTrialInsights